Modulating gut microbiota to enhance anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: the role of Lactobacillus kefiranofaciens and SOCS3 regulation
{{output}}
Immunotherapy targeting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) (PD-1/PD-L1) axis has revolutionized cancer treatment, yet its efficacy in hepatocellular carcinoma (HCC) remains limited. Emerging evidence suggests that gut mic... ...
